A Pilot Safety and Feasibility Study to Evaluate Motixafortide (CXCR4/SDF-1 Inhibition) and Natalizumab (VLA-4/VCAM-1 Inhibition) as a Novel Regimen to Mobilize CD34+ Hematopoietic Stem Cells for Gene Therapies in Sickle Cell Disease (SCD)
Overview
- Phase
- Phase 1
- Intervention
- Motixafortide
- Conditions
- Sickle Cell Disease
- Sponsor
- Washington University School of Medicine
- Enrollment
- 10
- Locations
- 1
- Primary Endpoint
- Safety and tolerability as assessed by the incidence of dose-limiting toxicities (DLTs)
- Status
- Completed
- Last Updated
- 8 months ago
Overview
Brief Summary
Hematopoietic stem cell (HSC)-based gene therapies now offer curative potential for patients with sickle cell disease (SCD), with decreased toxicity compared to allogeneic hematopoietic cell transplantation. However, effective HSC-based gene therapy depends on collecting sufficient HSCs to generate the therapeutic product, and currently available mobilization regimens carry unacceptable risk for patients with SCD or do not reliably yield optimal numbers of HSCs for gene therapy.
The investigators hypothesize that HSC mobilization with motixafortide (CXCR4i) alone and the combination of motixafortide plus natalizumab (VLA-4i) will be safe and tolerable in SCD patients. In addition, the investigators hypothesize that combined CXCR4 and VLA-4 blockade with motixafortide plus natalizumab will result in a rapid, robust, and synergistic increase in HSC mobilization to peripheral blood (PB) in patients with SCD, when compared to motixafortide alone.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Adult patients at least 18 years old
- •Diagnosis of sickle cell disease (hemoglobin SS or Sβ0 genotype)
- •Receiving automated RBC exchanges via apheresis-capable central venous access or willing to have apheresis-capable venous access placed.
- •Able to hold hydroxyurea, voxelotor, and/or crizanlizumab for at least 60 days prior to mobilization
- •Able to hold iron chelation for at least 7 days prior to mobilization
- •ECOG performance status ≤ 1
- •Normal bone marrow and organ function at screening as defined below:
- •Leukocytes ≥ 2,000/uL
- •Absolute neutrophil count ≥ 1,500/uL
- •Platelets ≥ 75,000/uL
Exclusion Criteria
- •Patients may not have a history of receiving the following therapies: prior HCT or prior gene therapy
- •Currently receiving concomitant immunosuppressants including 6-mercaptopurine, azathioprine, cyclosporine, methotrexate or concomitant inhibitors of TNF-α.
- •Patient may not have a history of significant alloantibodies which, in the opinion of the treating physician and study investigator, significantly increase the risk of participation in this clinical trial.
- •Currently receiving any other investigational agents.
- •A history of progressive multifocal leukoencephalopathy
- •A history of allergic reactions attributed to compounds of similar chemical or biologic composition to motixafortide or natalizumab.
- •Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection (including but not limited to HIV, active/untreated Hepatitis C and/or active/untreated Hepatitis B), ongoing/active vaso-occlusive pain crisis or uncontrolled SCD-related symptoms, symptomatic congestive heart failure, cerebrovascular accident, unstable angina pectoris, or cardiac arrhythmia.
- •Pregnant and/or breastfeeding. Women of childbearing potential must have a negative serum/urine pregnancy test within 7 days of study entry and prior to each study agent administration/HSC mobilization.
- •Determined by the investigator to be unable or unlikely to comply with the study procedures included in this protocol.
Arms & Interventions
Motixafortide followed by Motixafortide + Natalizumab
* Consenting and eligible patients will receive a single subcutaneous injection of motixafortide, followed by leukapheresis. Patient will then be followed for 8 weeks for adverse event monitoring. * Following the 8-week monitoring period, patients will receive a single IV infusion natalizumab, then approximately 32 hours later, a single subcutaneous injection of motixafortide, followed by leukapheresis. Patients will then be followed for 8 weeks for adverse event monitoring.
Intervention: Motixafortide
Motixafortide followed by Motixafortide + Natalizumab
* Consenting and eligible patients will receive a single subcutaneous injection of motixafortide, followed by leukapheresis. Patient will then be followed for 8 weeks for adverse event monitoring. * Following the 8-week monitoring period, patients will receive a single IV infusion natalizumab, then approximately 32 hours later, a single subcutaneous injection of motixafortide, followed by leukapheresis. Patients will then be followed for 8 weeks for adverse event monitoring.
Intervention: Natalizumab
Motixafortide followed by Motixafortide + Natalizumab
* Consenting and eligible patients will receive a single subcutaneous injection of motixafortide, followed by leukapheresis. Patient will then be followed for 8 weeks for adverse event monitoring. * Following the 8-week monitoring period, patients will receive a single IV infusion natalizumab, then approximately 32 hours later, a single subcutaneous injection of motixafortide, followed by leukapheresis. Patients will then be followed for 8 weeks for adverse event monitoring.
Intervention: Leukapheresis
Outcomes
Primary Outcomes
Safety and tolerability as assessed by the incidence of dose-limiting toxicities (DLTs)
Time Frame: Through 28 days following administration of either motixafortide and/or natalizumab (estimated to be 8 weeks and 4 days)
* All toxicities will be graded using NCI-CTCAE Version 5.0 * A DLT is an event occurring during the DLT period of 28 days following administration of either motixafortide and/or natalizumab that is considered to be at least possibly, probably or definitely related to study treatment by the investigator, and that meets the criteria below: * Hematologic criteria * Any Grade 5 adverse event * Any Grade 4 adverse event, excluding Grade 4 hemolysis, bilirubin increase, leukocytosis, erythrocytosis, thrombocytosis, anemia, leukopenia, or febrile neutropenia * Non-hematologic criteria * Any Grade 4 or 5 adverse event. * Any Grade 3 or higher arterial or venous thromboembolic event * Any Grade 2 or 3 adverse event that does not resolve within 4 weeks; with the exception of \<grade 2 injection site reactions.
Secondary Outcomes
- Number of CD34+ hematopoietic stem and progenitor cells (HSPCs) mobilized via leukapheresis per liter (L) of total volume (tV) processed following motixafortide alone and motixafortide + natalizumab(Day 2 and Day 60)
- Frequency of adverse events(From start of treatment through 8 weeks following completion of all treatment (estimated to be 16 weeks and 4 days))
- Change in peak CD34+ HSC mobilization in response to motixafortide alone and motixafortide + natalizumab in SCD patients, as assessed by CD34+ cells/ul in peripheral blood(From baseline through Day 60)
- Number of CD34+ hematopoietic stem and progenitor cells (HSPCs) mobilized via leukapheresis per liter (L) of adjusted volume (aV) processed, following motixafortide alone and motixafortide + natalizumab(Day 2 and Day 60)
- Change in kinetics of CD34+ HSC mobilization in response to motixafortide alone and motixafortide + natalizumab in SCD patients, as assessed by CD34+ cells/ul in peripheral blood(From baseline through Day 60)